Fidelity Investments’s AbbVie ABBV Stock Holding History

Fidelity Investments’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.73B	Sell	21,762,703 -846,686	-4%	-$188M	0.25%	55
2025 Q4	$5.17B	Buy	22,609,389 +1,574,302	+7%	+$359M	0.26%	40
2025 Q3	$4.87B	Buy	21,035,087 +33,470	+0.2%	+$6.82M	0.25%	44
2025 Q2	$3.9B	Sell	21,001,617 -2,634,965	-11%	-$490M	0.22%	60
2025 Q1	$4.95B	Buy	23,636,582 +5,539,207	+31%	+$1.08B	0.32%	37
2024 Q4	$3.22B	Buy	18,097,375 +4,466,971	+33%	+$821M	0.19%	73
2024 Q3	$2.69B	Buy	13,630,404 +511,470	+4%	+$95.5M	0.16%	95
2024 Q2	$2.25B	Buy	13,118,934 +630,537	+5%	+$104M	0.14%	111
2024 Q1	$2.27B	Buy	12,488,397 +1,397,770	+13%	+$241M	0.15%	101
2023 Q4	$1.72B	Sell	11,090,627 -180,845	-2%	-$26.4M	0.13%	128
2023 Q3	$1.68B	Buy	11,271,472 +371,842	+3%	+$54.6M	0.15%	121
2023 Q2	$1.47B	Sell	10,899,630 -1,985,856	-15%	-$291M	0.12%	137
2023 Q1	$2.05B	Sell	12,885,486 -1,478,010	-10%	-$226M	0.19%	98
2022 Q4	$2.32B	Sell	14,363,496 -655,720	-4%	-$101M	0.23%	78
2022 Q3	$2.02B	Sell	15,019,216 -2,392,966	-14%	-$343M	0.21%	80
2022 Q2	$2.67B	Sell	17,412,182 -1,194,012	-6%	-$182M	0.27%	60
2022 Q1	$3.02B	Buy	18,606,194 +1,542,954	+9%	+$224M	0.24%	57
2021 Q4	$2.31B	Sell	17,063,240 -4,553,434	-21%	-$538M	0.17%	94
2021 Q3	$2.33B	Sell	21,616,674 -13,840,304	-39%	-$1.58B	0.18%	92
2021 Q2	$3.99B	Sell	35,456,978 -1,206,825	-3%	-$136M	0.31%	48
2021 Q1	$3.97B	Buy	36,663,803 +7,609,661	+26%	+$814M	0.34%	41
2020 Q4	$3.11B	Sell	29,054,142 -1,203,037	-4%	-$116M	0.28%	54
2020 Q3	$2.65B	Sell	30,257,179 -1,112,935	-4%	-$105M	0.27%	54
2020 Q2	$3.08B	Sell	31,370,114 -3,636,195	-10%	-$320M	0.34%	43
2020 Q1	$2.67B	Sell	35,006,309 -5,232,576	-13%	-$446M	0.37%	42
2019 Q4	$3.56B	Buy	40,238,885 +2,928,045	+8%	+$243M	0.39%	42
2019 Q3	$2.83B	Buy	37,310,840 +10,566,142	+40%	+$724M	0.34%	48
2019 Q2	$1.94B	Buy	26,744,698 +13,544,557	+103%	+$1.06B	0.23%	78
2019 Q1	$1.06B	Buy	13,200,141 +4,765,946	+57%	+$390M	0.13%	146
2018 Q4	$778M	Sell	8,434,195 -273,259	-3%	-$24M	0.11%	173
2018 Q3	$824M	Buy	8,707,454 +1,574,495	+22%	+$149M	0.09%	192
2018 Q2	$661M	Sell	7,132,959 -11,268,487	-61%	-$1.1B	0.08%	249
2018 Q1	$1.74B	Buy	18,401,446 +3,496,715	+23%	+$384M	0.21%	101
2017 Q4	$1.44B	Buy	14,904,731 +6,469,978	+77%	+$610M	0.17%	119
2017 Q3	$750M	Buy	8,434,753 +1,938,588	+30%	+$148M	0.09%	229
2017 Q2	$471M	Sell	6,496,165 -395,242	-6%	-$26.6M	0.06%	325
2017 Q1	$449M	Buy	6,891,407 +745,555	+12%	+$46.9M	0.06%	356
2016 Q4	$385M	Sell	6,145,852 -5,123,067	-45%	-$313M	0.05%	402
2016 Q3	$706M	Sell	11,268,919 -3,342,032	-23%	-$216M	0.09%	224
2016 Q2	$896M	Sell	14,610,951 -11,464,820	-44%	-$699M	0.12%	174
2016 Q1	$1.49B	Sell	26,075,771 -18,081,533	-41%	-$1.01B	0.21%	93
2015 Q4	$2.62B	Buy	44,157,304 +4,303,452	+11%	+$248M	0.35%	47
2015 Q3	$2.17B	Buy	39,853,852 +8,356,232	+27%	+$544M	0.31%	57
2015 Q2	$2.12B	Buy	31,497,620 +10,103,184	+47%	+$660M	0.27%	65
2015 Q1	$1.25B	Sell	21,394,436 -12,676,377	-37%	-$766M	0.16%	143
2014 Q4	$2.23B	Sell	34,070,813 -47,266,208	-58%	-$2.98B	0.29%	65
2014 Q3	$4.7B	Buy	81,337,021 +24,251,445	+42%	+$1.35B	0.64%	18
2014 Q2	$3.22B	Sell	57,085,576 -12,123,971	-18%	-$636M	0.43%	39
2014 Q1	$3.56B	Sell	69,209,547 -3,935,295	-5%	-$199M	0.49%	34
2013 Q4	$3.86B	Buy	73,144,842 +13,164,507	+22%	+$647M	0.55%	24
2013 Q3	$2.68B	Buy	59,980,335 +1,445,261	+2%	+$64.1M	0.41%	44
2013 Q2	$2.42B	Buy	+58,535,074	New	+$2.56B	0.4%	45

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fidelity Investments's ABBV Position: Q1 2026 in Review

Fidelity Investments reduced its AbbVie (ABBV) stake by 3.7% in Q1 2026, selling an estimated $188M and leaving 21,762,703 shares worth $4.73B. The position accounts for 0.25% of the portfolio, ranked #55.

Fidelity Investments first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $5.17B in Q4 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Fidelity Investments held 21,762,703 shares of AbbVie worth $4.73B as of Q1 2026.
Fidelity Investments sold 846,686 AbbVie shares in Q1 2026, an estimated $188M.
AbbVie made up 0.25% of Fidelity Investments's portfolio in Q1 2026, its #55 holding.
Fidelity Investments first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
Fidelity Investments's AbbVie position peaked at $5.17B in Q4 2025.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.